Activated phosphoinositide 3-kinase delta syndrome: report of seven cases

LIU Qing-Hua; PENG Li; HUANG Han; DENG Liang-Ji; ZHONG Li-Li

doi:10.7499/j.issn.1008-8830.2312065

PDF(2016 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (5) : 499-505. DOI: 10.7499/j.issn.1008-8830.2312065

CLINICAL RESEARCH

Activated phosphoinositide 3-kinase delta syndrome: report of seven cases

LIU Qing-Hua, PENG Li, HUANG Han, DENG Liang-Ji, ZHONG Li-Li

Author information +

History +

Abstract

Objective To summarize the clinical data of 7 children with activated phosphoinositide 3-kinase delta syndrome (APDS) and enhance understanding of the disease. Methods A retrospective analysis was conducted on clinical data of 7 APDS children admitted to Hunan Provincial People's Hospital from January 2019 to August 2023. Results Among the 7 children (4 males, 3 females), the median age of onset was 30 months, and the median age at diagnosis was 101 months. Recurrent respiratory tract infections, hepatosplenomegaly, and multiple lymphadenopathy were observed in all 7 cases. Sepsis was observed in 5 cases, otitis media and multiple caries were observed in 3 cases, and diarrhea and joint pain were observed in 2 cases. Lymphoma and systemic lupus erythematosus were observed in 1 case each. Fiberoptic bronchoscopy was performed in 4 cases, revealing scattered nodular protrusions in the bronchial lumen. The most common respiratory pathogen was Streptococcus pneumoniae (4 cases). Six patients had a p.E1021K missense mutation, and one had a p.434-475del splice site mutation. Conclusions p.E1021K is the most common mutation site in APDS children. Children who present with one or more of the following symptoms: recurrent respiratory tract infections, hepatosplenomegaly, multiple lymphadenopathy, otitis media, and caries, and exhibit scattered nodular protrusions on fiberoptic bronchoscopy, should be vigilant for APDS. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(5): 499-505

Key words

Activated phosphoinositide 3-kinase delta syndrome / Recurrent respiratory tract infection / Hepatosplenomegaly / Lymphadenopathy / Nodular protrusion / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIU Qing-Hua, PENG Li, HUANG Han, DENG Liang-Ji, ZHONG Li-Li. Activated phosphoinositide 3-kinase delta syndrome: report of seven cases[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(5): 499-505 https://doi.org/10.7499/j.issn.1008-8830.2312065

References

1 杨夏影, 马银娟, 潘耀柱. PI3Kδ过度活化综合征诊疗进展[J]. 中国现代医学杂志, 2021, 31(6): 71-78. DOI: 10.3969/j.issn.1005-8982.2021.06.013.
2 唐文静, 王薇, 罗颖, 等. PIK3CD基因突变致PI3Kδ过度活化综合征临床及免疫学特点分析[J]. 中华儿科杂志, 2017, 55(1): 19-24. PMID: 28072954. DOI: 10.3760/cma.j.issn.0578-1310.2017.01.004.
3 Thauland TJ, Pellerin L, Ohgami RS, et al. Case study: mechanism for increased follicular helper T cell development in activated PI3K delta syndrome[J]. Front Immunol, 2019, 10: 753. PMID: 31031754. PMCID: PMC6473200. DOI: 10.3389/fimmu.2019.00753.
4 Rathinaswamy MK, Burke JE. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease[J]. Adv Biol Regul, 2020, 75: 100657. PMID: 31611073. DOI: 10.1016/j.jbior.2019.100657.
5 Angulo I, Vadas O, Gar?on F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage[J]. Science, 2013, 342(6160): 866-871. PMID: 24136356. PMCID: PMC3930011. DOI: 10.1126/science.1243292.
6 Jamee M, Moniri S, Zaki-Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3Kδ syndrome (APDS): a systematic review[J]. Clin Rev Allergy Immunol, 2020, 59(3): 323-333. PMID: 31111319. DOI: 10.1007/s12016-019-08738-9.
7 Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study[J]. J Allergy Clin Immunol, 2017, 139(2): 597-606.e4. PMID: 27555459. PMCID: PMC5292996. DOI: 10.1016/j.jaci.2016.06.021.
8 Redenbaugh V, Coulter T. Disorders related to PI3Kδ hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes[J]. Front Pediatr, 2021, 9: 702872. PMID: 34422726. PMCID: PMC8374435. DOI: 10.3389/fped.2021.702872.
9 Aytenfisu TY, Campbell HM, Chakrabarti M, et al. Class I PI3K biology[J]. Curr Top Microbiol Immunol, 2022, 436: 3-49. PMID: 36243838. DOI: 10.1007/978-3-031-06566-8_1.
10 Preite S, Gomez-Rodriguez J, Cannons JL, et al. T and B-cell signaling in activated PI3K delta syndrome: from immunodeficiency to autoimmunity[J]. Immunol Rev, 2019, 291(1): 154-173. PMID: 31402502. DOI: 10.1111/imr.12790.
11 Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation[J]. J Allergy Clin Immunol, 2019, 143(5): 1676-1687. PMID: 31060715. DOI: 10.1016/j.jaci.2019.03.017.
12 Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study[J]. J Allergy Clin Immunol, 2016, 138(1): 210-218.e9. PMID: 27221134. DOI: 10.1016/j.jaci.2016.03.022.
13 Sinclair LV, Finlay D, Feijoo C, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking[J]. Nat Immunol, 2008, 9(5): 513-521. PMID: 18391955. PMCID: PMC2857321. DOI: 10.1038/ni.1603.
14 Singh A, Joshi V, Jindal AK, et al. An updated review on activated PI3 kinase delta syndrome (APDS)[J]. Genes Dis, 2020, 7(1): 67-74. PMID: 32181277. PMCID: PMC7063426. DOI: 10.1016/j.gendis.2019.09.015.
15 Gathmann B, Mahlaoui N, CEREDIH, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency[J]. J Allergy Clin Immunol, 2014, 134(1): 116-26. PMID: 24582312. DOI: 10.1016/j.jaci.2013.12.1077.
16 Cohen JI. Herpesviruses in the activated phosphatidylinositol-3-kinase-δ syndrome[J]. Front Immunol, 2018, 9: 237. PMID: 29599765. PMCID: PMC5863522. DOI: 10.3389/fimmu.2018.00237.
17 Zhang Q, Ma H, Ma J, et al. Clinical and genetic analysis of immunodeficiency-related diseases associated with PIK3CD mutations[J]. Pediatr Investig, 2018, 2(4): 257-262. PMID: 32851276. PMCID: PMC7331349. DOI: 10.1002/ped4.12101.
18 Wang Y, Wang W, Liu L, et al. Report of a Chinese cohort with activated phosphoinositide 3-kinase δ syndrome[J]. J Clin Immunol, 2018, 38(8): 854-863. PMID: 30499059. DOI: 10.1007/s10875-018-0568-x.
19 Ezaizi Y, Manini ML, Absah I. Gastrointestinal mucosal lymphoid hyperplasia: mutation in PIK3CD gene[J]. J Pediatr Gastroenterol Nutr, 2020, 71(1): e46. PMID: 31703042. DOI: 10.1097/MPG.0000000000002552.
20 Marzollo A, Bresolin S, Colavito D, et al. Case report: intestinal nodular lymphoid hyperplasia as first manifestation of activated PI3Kδ syndrome due to a novel PIK3CD variant[J]. Front Pediatr, 2021, 9: 703056. PMID: 34692603. PMCID: PMC8528001. DOI: 10.3389/fped.2021.703056.
21 Williams SN. Endoscopic airway manifestations in a pediatric patient with activated PI3K-delta syndrome[J]. Pediatr Pulmonol, 2020, 55(11): 2836-2837. PMID: 32969594. DOI: 10.1002/ppul.25021.
22 Carpier JM, Lucas CL. Epstein-Barr virus susceptibility in activated PI3Kδ syndrome (APDS) immunodeficiency[J]. Front Immunol, 2018, 8: 2005. PMID: 29387064. PMCID: PMC5776011. DOI: 10.3389/fimmu.2017.02005.
23 Lougaris V, Cancrini C, Rivalta B, et al. Activated phosphoinositide 3-dinase delta syndrome (APDS): an update[J]. Pediatr Allergy Immunol, 2022, 33(Suppl 27): 69-72. PMID: 35080319. PMCID: PMC9543808. DOI: 10.1111/pai.13634.
24 Vanselow S, Wahn V, Schuetz C. Activated PI3Kδ syndrome: reviewing challenges in diagnosis and treatment[J]. Front Immunol, 2023, 14: 1208567. PMID: 37600808. PMCID: PMC10432830. DOI: 10.3389/fimmu.2023.1208567.
25 Kang JM, Kim SK, Kim D, et al. Successful sirolimus treatment for Korean patients with activated phosphoinositide 3-kinase δ syndrome 1: the first case series in Korea[J]. Yonsei Med J, 2020, 61(6): 542-546. PMID: 32469178. PMCID: PMC7256007. DOI: 10.3349/ymj.2020.61.6.542.
26 Condliffe AM, Chandra A. Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome[J]. Front Immunol, 2018, 9: 338. PMID: 29556229. PMCID: PMC5844940. DOI: 10.3389/fimmu.2018.00338.
27 Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome[J]. J Allergy Clin Immunol, 2022, 149(1): 410-421.e7. PMID: 34033842. PMCID: PMC8611111. DOI: 10.1016/j.jaci.2021.04.036.
28 Laberko A, Mukhinа A, Machneva E, et al. Allogeneic hematopoietic stem cell transplantation activity in inborn errors of immunity in Russian federation[J]. J Clin Immunol, 2023, 43(6): 1241-1249. PMID: 37009957. PMCID: PMC10068234. DOI: 10.1007/s10875-023-01476-w.
29 Yang X, Xi R, Bai J, et al. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: case report and literature review[J]. Medicine (Baltimore), 2023, 102(5): e32816. PMID: 36749229. PMCID: PMC9902017. DOI: 10.1097/MD.0000000000032816.